Company intelligence / Profile preview

Laysan Bio

Arab, Alabama, United Stateslaysanbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Laysan Bio manufactures and supplies activated poly(ethylene glycol) reagents that have been used in seven FDA or EU-approved drug products or medical devices including Neulasta®, Somavert®, PEGASYS®, PEG-INTRON®, Definity®, Macugen® and DuraSealTM. The company supports customers from research to commercialization with compliant manufacturing capabilities.

Modalities: Polymer-drug conjugate therapy (PEGylation)Polymer (polyethylene glycol reagents)
Industry: Chemicals & Materials

Partnerships

Supplies to academic institutions, biotech companies, pharmaceutical developers

Beyond the preview

Go deeper on Laysan Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laysan Bio.

Explore the full profile